Global Metastatic Colorectal Cancer Market - 2023-2030

Overview

Global Metastatic Colorectal Cancer Market reached US$ 3.4 billion in 2022 and is expected to reach US$ 4.8 billion by 2030 growing with a CAGR of 4.6% during the forecast period 2023-2030. The metastatic colorectal cancer market is driven by factors such as increasing incidence and prevalence, increased research and development activities, and government initiatives.

Genetic variables, interactions with the tumor microenvironment, and other external factors all play a role in colorectal metastasis. Three types of therapeutic treatments can be used to treat metastatic colorectal cancer (mCRC): systemic chemotherapy, targeted therapy, and immunotherapy.

Market Dynamics

The Increasing FDA Approval for Metastatic Colorectal Cancer Treatment is Driving the Global Metastatic Colorectal Cancer Market Growth

In January 2023, Tucatinib (Tukysa, Seagen Inc.) and trastuzumab received accelerated approval from the Food and Drug Administration for the treatment of RAS wild-type HER2-positive metastatic or unresectable colorectal cancer that has progressed after receiving fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy. An open-label, multicenter experiment called MOUNTAINEER (NCT03043313) examined effectiveness in 84 patients.

Patients had treatment with fluoropyrimidine, oxaliplatin, irinotecan, and an anti-vascular endothelial growth factor (VEGF) monoclonal antibody (mAb) in the past for colorectal cancer that was HER2-positive, RAS wild-type, unresectable or metastatic. Patients who needed to get an anti-programmed cell death protein-1 mAb also had tumors that lacked mismatch repair (dMMR) proteins or had high microsatellite instability (MSI-H).

The Increasing Research Activities are Driving the Global Metastatic Colorectal Cancer Market Growth

In May 2023, Takeda and HUTCHMED (China) Limited reported that the FDA granted priority review of the New Drug Application (NDA) for fruquintinib, a highly potent and selective inhibitor of VEGFR-1, -2, and -3 for the treatment of adult patients with metastatic colorectal cancer (CRC) who have already received treatment.

If authorized, fruquintinib will be the first and only highly selective inhibitor of each of the three VEGF receptors authorized in the United States for metastatic CRC that has already received treatment. The FDA set November 30, 2023, as the Prescription Drug User Fee Act (PDUFA) goal date for this NDA.

Side Effects Associated with Metastatic Colorectal Cancer Therapy are Hampering the Global Metastatic Colorectal Cancer Market Growth

Side effects associated with metastatic colorectal cancer therapy restraining the market growth. Cancer cells are among the fast-dividing cells that chemotherapy treatments target. They can, impact healthy cells, resulting in a number of adverse consequences. Nausea and vomiting, fatigue, hair loss, diarrhea or constipation, bone marrow suppression (lowered blood cell counts), mouth sores, and neuropathy (nerve damage) are typical adverse effects of chemotherapy used to treat mCRC.

Targeted therapies concentrate on specific chemicals implicated in the development of cancer. Targeted therapy for metastatic colorectal cancer (mCRC) frequently causes side effects such as skin reactions (rash, dryness), hypertension (high blood pressure), gastrointestinal problems (diarrhea, nausea), fatigue, abnormalities in liver enzymes, and an increased risk of bleeding or blood clotting.

For more details on this report - Request for Sample

Segment Analysis

The global metastatic colorectal cancer market is segmented based on treatment, drug class, end-user and region.

The Chemotherapy Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The chemotherapy segment accounted for the highest market stake accounting for approximately 41.3% of the metastatic colorectal cancer market in 2022. As per the article published in the International Journal of Molecular Sciences in 2023, For mCRC, cytotoxic chemotherapy is still the go-to treatment option. The foundation of combination regimens is made up primarily of fluoropyrimidines.

First-line therapy for metastatic colorectal cancer (mCRC) involves chemotherapy, such as FOLFOX (fluorouracil, leucovorin, and oxaliplatin), FOLFIRI (fluorouracil, leucovorin, and irinotecan), or FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan), either alone or in combination with.

Geographical Penetration

North America Holds a Dominant Position in the Global Metastatic Colorectal Cancer Market

North America is estimated to hold around 39.6% of the total market share in 2023. In September 2022, for patients with metastatic colon cancer for whom traditional therapy is no longer effective, a new phase 2 clinical trial directed by Robert Lentz, MD, a member of the University of Colorado Cancer Centre, may provide hope. In the United States, colorectal cancer is the third most prevalent and third most lethal cancer in both men and women. Furthermore, there are not many viable therapeutic alternatives available once chemotherapy and biological therapy cease to be successful in patients.

The issue is exacerbated by the fact that around 95% of colorectal cancer patients do not respond to immune treatment medications that have already received approval. In order to extend these patients' lives, they must be finding a means to trigger an anti-tumor immune response.

Competitive Landscape

The major global players in the market include: Amgen, EMD Serono, Eli Lilly, Genentech, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Sanofi, Suzhou Zelgen Biopharmaceuticals, and Taiho Oncology among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war may affect the metastatic colorectal cancer market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. For cancer treatments to advance, clinical trials are necessary. As a result of the disagreement, new treatments for mCRC may take longer to develop, enrolment of new patients may be delayed, and proper data collecting may be hampered. Infrastructure and healthcare facilities may be destroyed or overburdened during a conflict. This might make it more difficult to give mCRC patients supportive care and specialized cancer therapies.

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the metastatic colorectal cancer market to improve various aspects of data analysis. To find prospective treatment candidates and molecular targets for metastatic colorectal cancer, AI is utilized in drug discovery to analyze complicated biological and genomic data. By foreseeing potential drug interactions with certain tumor mutations, it can quicken the drug development process.

By Treatment

• Chemotherapy
• Targeted Therapies
• Immunotherapies
• Monotherapy and Combination Therapy
• Others

By Drug class

• Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors
• Anti-VEGF (Vascular Endothelial Growth Factor) Therapies
• Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies
• Immune Checkpoint Inhibitors
• Others

By End-user

• Hospitals
• Cancer Centers
• Ambulatory Surgical Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• In August 2023, Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. reported that the U.S. Food and Drug Administration approved LONSURF (trifluridine/tipiracil) as a single agent or in combination with bevacizumab for the therapy of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

Why Purchase the Report?

• To visualize the global metastatic colorectal cancer market segmentation based on the treatment, drug class, end-user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of metastatic colorectal cancer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global metastatic colorectal cancer market report would provide approximately 61 tables, 57 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies